Noteable wrote: The analysis included reports from 169 clinical trials encompassing 22,492 patients. Multiple types of ADCs were included, and several cancer types were represented.
Overall, there were more than 600 types of adverse events reported across the trials. The overall incidence of TRAEs was 91.2%, and the incidence of grade 3 or higher TRAEs was 46.1%. The incidence of treatment discontinuation due to TRAEs was 13.2%, and the rate of fatal TRAEs was 1.3%.
The most common all-grade TRAEs were lymphopenia (53.0%), nausea (44.1%), neutropenia (43.7%), blurred vision (40.5%), and peripheral neuropathy (39.6%).
The most common grade 3 or higher TRAEs were neutropenia (31.2%), hypoesthesia (23.3%), thrombocytopenia (22.6%), febrile neutropenia (21.2%), and lymphopenia (21.0%).
The ADCs with the highest rates of allgrade TRAEs were trastuzumab deruxtecan (98.0%), polatuzumab vedotin (97.7%), sacituzumab govitecan (97.1%), patritumab deruxtecan (96.3%), tisotumab vedotin (96.0%), and trastuzumab emtansine (95.7%).
The highest mean incidences of all-grade TRAEs were seen in patients with breast cancer (97.2%), urinary cancer (93.9%), and lymphoma (91.0%). The highest mean incidences of grade 3 or higher TRAEs were seen in patients with lymphoma (65.4%), leukemia (62.4%), and lung cancer (51.8%).
Subgroup analyses suggested that several patient groups had a higher risk of allgrade TRAEs, including those with breast cancer, those treated with topoisomerase I inhibitor-based ADCs (vs pyrrolobenzodiazepinebased ADCs), and those who received antiHER2 ADCs (vs antiCD19 ADCs).